| 摘要: |
| 目的:研究重组人血管内皮抑素恩度联合替吉奥联合奥沙利铂(SOX)方案治疗晚期结直肠癌的临床疗效及对患者血清标志物细胞间黏附因子-1(ICAM-1)和血管细胞黏附因子-1(VCAM-1)水平的影响。方法:选取2010年1月—2015年1月于大连大学附属新华医院就诊并经病理组织学证实的晚期结直肠癌患者127例，随机分为治疗组和对照组，对照组64例采用SOX方案治疗，治疗组63例给予重组人血管内皮抑素恩度联合SOX方案。比较两组的近期及远期疗效、生命质量和不良反应，以及治疗前后血清ICAM-1和VCAM-1水平的变化。结果:治疗组的近期总有效率(ORR)为60.32%(38/63)，高于对照组的42.19%(27/64)，差异有统计学意义(χ2 =4.177，P=0.044)；治疗组的疾病控制率(DCR)为82.54%(52/63)，高于对照组的67.19%(43/64)，差异有统计学意义(χ2 =3.970，P=0.046)；两组患者的远期总生存情况差异无统计学意义(P=0.67)；治疗后，两组的生命质量稳定或改善率差异无统计学意义(χ2 =1.624，P=0.203)；两组患者治疗期间各类不良反应发生率相近。治疗后，两组患者的ICAM-1与VCAM-1水平均较治疗前降低(P<0.05)，且治疗组的ICAM-1、VCAM-1水平低于对照组，差异有统计学意义(P<0.05)。结论:重组人血管内皮抑素联合SOX方案可以降低患者血清ICAM-1及VCAM-1水平，在不增加不良反应发生率的基础上取得更好的近期疗效。 |
| 关键词: 重组人血管内皮抑素 结直肠癌 细胞间黏附因-1 血管细胞黏附因子-1 替吉奥联合奥沙利铂 |
| DOI：10.3969/j.issn.1007-6948.2021.02.027 |
| 投稿时间：2020-04-25 |
| 基金项目: |
|
| Therapeutic Effect of Recombinant Human Endostatin Combined with SOX Regimen on Patients with Advanced Colorectal Cancer and its Changes of Serum ICAM-1 and VCAM-1 |
| YU Deng-feng,ZHANG Wen-jun,ZHANG Fu-jie |
| Department of Anorectal Surgery, Dalian University affiliated Xinhua Hospital, Dalian 116021, China |
| Abstract: |
| Objective To study the therapeutic effect of recombinant human endostatin combined with SOX regimen on patients with advanced colorectal cancer and its changes of serum ICAM-1 and VCAM-1. Methods A total of 127 patients with late colorectal cancer between January 2010 and January 2015 were randomly assigned to treatment group (63) and control group (64). The treatment group was treated with recombinant human endostatin combined with SOX regimen, and the control group was treated with SOX alone. The short-term and long-term efficacy, quality of life and adverse reactions of the two groups and the changes of serum ICAM-1 and VCAM-1 before and after treatment were compared. Results The total effective rate (ORR) of the treatment group and the control group were 60.32% (38/63) and 42.19% (27/64), respectively resulting statistically significant (χ2 =4.177, P=0.044). The disease control rate (DCR) of the two groups was 82.54% (52/63) and 67.19% (43/64) (χ2 =3.970, P=0.046). The 3-year overall survival rate (log-rank, P=0.67) was not statistically significant between the two groups. The quality of life were similar between two groups. Additionally, there was no statistically significant difference between the two groups in the incidence of adverse events. The levels of ICAM-1 and VCAM-1 in the two groups were lower than those before treatment (P<0.05), and the levels of ICAM-1 and VCAM-1 in the treatment group were lower than those in the control group (P<0.05). Conclusion The use of recombinant human endostatin combined with SOX could decline the expression of serum ICAM-1 and VCAM-1, which could achieve a better short-term outcome with similar incidence of adverse reactions. |
| Key words: Recombinant human endostatin colon and rectal cancer ICAM-1 VCAM-1 SOX |
